C0576773||Subcutaneous
C0444889||Continuous Infusion
C0019134||Heparin
C0243026||Sepsis
C0243026||Sepsis
C0243042||inflammatory mediators
C1704259||coagulation pathway
C2825026||Unfractionated heparin
C0003209||anti-inflammatory agent
C0243026||sepsis
C0026766||organ failure
C0243026||sepsis
C1328723||coagulation process
C0681814||study
C0019134||heparin
C0243026||sepsis
C0032105||Plasma
C0030190||plasminogen activator inhibitor-1
C0030190||plasminogen activator inhibitor-1
C0243042||inflammatory mediator
C2347341||necoutrophil gelatinase-associated lipocalin
C2347341||necoutrophil gelatinase-associated lipocalin
C0005516||marker
C0160420||kidney injury
C0033522||prospective
C0206035||randomized controlled trial
C1547114||bed
C0021708||intensive care unit
C0243026||sepsis
C0034656||randomized
C0019134||heparin
C0019134||heparin
C1736929||subcutaneously
C0032105||plasma
C0030190||plasminogen activator inhibitor-1
C2347341||necoutrophil gelatinase-associated lipocalin
C0243095||day 0
C0441994||lower
C0032105||plasma
C0030190||plasminogen activator inhibitor-1
C2347341||necoutrophil gelatinase-associated lipocalin
C0441994||lower
C2347341||necoutrophil gelatinase-associated lipocalin
C0489438||acute physiology and chronic health evaluation (APACHE) II
C3494459||sequential organ failure assessment (SOFA) scores
C0243095||day 0
C0019134||heparin
C0443315||subcutaneous
C0019134||heparin
C0032105||plasma
C0030190||plasminogen activator inhibitor-1
C2347341||necoutrophil gelatinase-associated lipocalin
C0019134||heparin